TABLE 1

Clinical characteristics of patient samples

SampleSex (M/F)Age (years)BMI (kg/m2)Fasting plasma glucose (mmol/l)A1C (%) or plasma glucose at 2-h OGTT (mmol/l)
GCI USA C/C
    Diabetes644/58263 ± 1133 ± 79.8 ± 3.08.0 ± 3.1
    NGT644/58261 ± 1027 ± 55.1 ± 0.9ND
GCI Poland C/C
    Diabetes422/58762 ± 1030 ± 58.9 ± 4.07.9 ± 1.3
    NGT422/58759 ± 726 ± 44.8 ± 1.2ND
Scandinavian trios
    Probands168/15339 ± 927 ± 57.2 ± 2.68.5 ± 2.9
    Parents236/236
Sibships
    Diabetes/severe IGT sibling280/32965 ± 1029 ± 59.3 ± 3.314.3 ± 5.6
    NGT sibling275/30562 ± 1026 ± 35.4 ± 0.46.0 ± 1.1
Scandinavia C/C
    Diabetes/severe IGT252/21960 ± 1028 ± 59.8 ± 3.415.0 ± 5.3
    NGT254/21760 ± 1027 ± 46.2 ± 1.86.8 ± 2.8
Sweden C/C
    Diabetes267/24766 ± 1228 ± 48.5 ± 2.56.5 ± 1.5
    NGT267/24766 ± 1228 ± 44.8 ± 0.7ND
Canada C/C
    Diabetes70/5753 ± 829 ± 56.4 ± 1.812.8 ± 2.1
    NGT70/5752 ± 829 ± 45.1 ± 0.66.1 ± 1.1
  • Data are n or the means ± SD. Plasma glucose was measured at baseline (fasting) and 2 h after an oral glucose tolerance test. C/C, case control; GCI, Genomics Collaborative; IGT, impaired glucose tolerance; ND, not determined; NGT, normal glucose tolerance; OGTT, oral glucose tolerance test.